Vuja De Sciences
HOBOKEN, NJ · Other · 9 employees
Vuja De is dedicated to developing cancer metastasis treatments that prevent cancer progression and recurrence. Our strategy is to develop products first for osteosarcoma, a rare bone cancer that largely effects adolescents, and then extend to other cancers. We utilize leading laboratory technologies for metastatic preclinical endpoints in combination with Comparative Oncology to de-risk and info
Funding history
- Series seed — $370K — Oct 2024
- Series seed — $700K — May 2024
- Series seed — $391K — Oct 2023
- Series seed — $875K — Nov 2022
- Series seed — $1.2M — Jun 2021
Recent signals
- Oct 17, 2024: Raised $370K in Series seed
- May 28, 2024: Raised $700K in Series seed
- Oct 30, 2023: Raised $391K in Series seed
- Nov 29, 2022: Raised $875K in Series seed
- Jun 15, 2021: Raised $1.2M in Series seed
- May 15, 2020: Raised $387K in Series seed
- May 20, 2019: Raised $501K in Series seed
See plans & pricing → Track Vuja De Sciences’s funding, hiring, and signals — with verified contacts — on Fundz.